Reme-D closes $1.45 million pre-Series A
Anara Impact Capital led funding to expand diagnostic manufacturing and market access.
Reme-D closed a $1.45 million pre-Series A round, announced on 20 July 2026. Anara Impact Capital led, with participation from Global Innovation Fund and Africa Health Ventures.
The company planned to expand manufacturing capacity, enter additional African markets and develop tests for genetic diseases and cancer. Reme-D manufactures molecular diagnostics designed to make testing more accessible in underserved healthcare settings.
Use of funds
Manufacturing expansion
Diagnostic product development
African market expansion